Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis

Journal of Immunology

Volumn 177, Issue 9, 2006, Pages 6433-6439

  Kamata, Koichi ^a   Kamijo, Seiji ^a   Nakajima, Atsuo ^a,b   Koyanagi, Akemi ^a   Kurosawa, Hisashi ^a   Yagita, Hideo ^a   Okumura, Ko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMURON; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TWEAK; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS PROTEIN; TWEAK PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRITIS; ARTICLE; CELL DEATH; CELL HYPERPLASIA; CELL INFILTRATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; COLLAGEN INDUCED ARTHRITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATION; KNEE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PAW EDEMA; PRIORITY JOURNAL; SYNOVITIS;

EID: 33750350777     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.9.6433     Document Type: Article

References (48)

1. Chicheportiche, Y., P. R. Bourdon, H. Xu, Y. M. Hsu, H. Scott, C. Hession, I. Garcia, and J. L. Browning. 1997. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272: 32401-32410.
2. Nakayama, M., Y. Kayagaki, N. Yamaguchi, K. Okumura, and H. Yagita. 2000. Involvement of TWEAK in interferon-γ-stimulated monocyte cytotoxicity. J. Exp. Med. 192: 1373-1380.
3. Wiley, S. R., L. Cassiano, T. Lofton, T. Davis-Smith, J. A. Winkles, V. Lindner, H. Liu, T. O. Daniel, C. A. Smith, and W. C. Fanslow. 2001. A Novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15: 837-846.
4. Nakayama, M., K. Ishidoh, Y. Kojima, N. Harada, E. Kominami, K. Okumura, and H. Yagita. 2003. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J. Immunol. 170: 341-348.
5. Harada, N., M. Nakayama, H. Nakano, Y. Fukuchi, H. Yagita, and K. Okumura. 2002. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 299: 488-493.
6. Lynch, C. N., Y. C. Wang, J. K. Lund, Y. W. Chen, J. A. Leal, and S. R. Wiley. 1999. TWEAK induces angiogenesis and proliferation of endothelial cells. J. Biol. Chem. 272: 8455-8459.
7. Chicheportiche, Y., R. Chicheportiche, I. Sizing, J. Thompson, C. B. Benjamin, C. Ambrose, and J. M. Dayer. 2002. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res. 4: 126-133.
8. Chicheportiche, Y., L. Fossati-Jimack, S. Moll, N. Ibnou-Zekri, and S. Izui. 2000. Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem. Biophys. Res. Commun. 279: 162-165.
9. Nakayama, M., N. Harada, E. Kominami, K. Okumura, and H. Yagita. 2003. Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem. Biophys. Res. Commun. 306: 819-825.
10. Feldman, M., and R. N. Maini. 2001. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19: 163-196.
11. Charles, P., M. J. Elliott, D. Davis, A. Potter, J. R. Kalden, C. Antoni, F. C. Breedveld, J. S. Smolen, G. Eberl, K. deWoody, et al. 1999. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J. Immunol. 163: 1521-1528.
12. Paleolog, E. M., S. Young, A. C. Stark, R. V. Closkey, M. Feldman, and R. N. Maini. 1998. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 41: 1258-1265.
13. Tailor, P. C., A. M. Peters, E. Paleolog, P. T. Chapman, M. J. Elliott, R. McCloskey, M. Feldman, and R. N. Maini. 2000. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43: 38-47.
14. Paleolog, E. M., M. Hunt, M. J. Elliott, M. Feldman, R. N. Maini, and J. N. Woody. 1996. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum. 39: 1082-1091.
15. Tak, P. P., P. C. Taylor, F. C. Breedveld, T. J. M. Smeets, M. R. Daha, P. M. Kluin, A. E. Meinders, and R. N. Maini. 1996. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 39: 1077-1081.
16. Maini, R. N., P. C. Taylor, E. Paleolog, P. Charles, S. Ballara, F. M. Brennan, and M. Feldman. 1999. Anti-tumor necrosis factor specific antibody (infliximab) treatment provides insights into pathophysiology of rheumatoid arthritis. Ann. Rheum. Dis. 58(Suppl. 1): 156-1:60.
17. Brennan, F. M., K. A. Browne, P. A. Green, J. M. Jasper, R. N. Maini, and M. Feldmann. 1997. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-α (cA2) therapy. Br. J. Rheumatol. 36: 643-650.
18. Stuart, J. M., A. S. Townes, and A. H. Kang. 1982. Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice. J. Clin. Invest. 69: 673-683.
19. Iwai, H., Y. Kozono, S. Hirose, H. Akiba, H. Yagita, K. Okumura, H. Kohsaka, N. Miyasaka, and M. Azuma. 2002. Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J. Immunol. 169: 4332-4339.
20. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171: 6173-6177.
21. Malfait, A. M., D. M. Butler, D. H. Presky, R. N. Maini, F. M. Brennan, and M. Feldman. 1998. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. 111: 377-383.
22. Sumariwalla, P. F., A. M. Malfait, and M. Feldmann. 2004. P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor. Clin. Exp. Immunol. 136: 67-75.
23. Nakajima, A., M. Azuma, S. Kodera, S. Nuriya, A. Terashi, M. Abe, S. Hirose, T. Shirai, H. Yagita, and K. Okumura. 1995. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Eur. J. Immunol. 25: 3060-3069.
24. Cook, A. D., E. L. Braine, I. K. Cambell, and J. A. Hamilton. 2002. Differing roles for urokinase and tissue-type plaminogen activator in collagen-induced arthritis. Am. J. Pathol. 160: 917-926.
25. Kim, J., S. Ho, E. Park, W. Hahn, H. Cho, J. Jeong, Y. Lee, and S. Kim. 2002. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum. 46: 793-801.
26. Mould, A. W., I. D. Tonks, M. M. Cahill, A. R. Pettit, R. Thomas, N. K. Hayward, and G. F. Kay. 2003. Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum. 48: 2660-2669.
27. Koch, A. E., S. L. Kunkel, L. A. Harlow, B. Johnson, H. L. Evanoff, G. Kenneth Haines, M. D. Burdick, R. M. Pope, and R. M. Strieter. 1992. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest. 90: 772-779.
28. Huber, A. R., S. L. Kunkel, R. F. Todd, and S. J. Weiss. 1991. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 254: 99-102.
29. Roberts, P. J., A. R. Pizzey, A. Khwaja, J. E. Carver, A. R. Mire-Sluis, and D. C. Linch. 1993. The effect of IL-1 on neutrophil f-Met-Leu-Phe receptors, CD11b expression and metabolic activity, in comparison and combination with other cytokines. Br. J. Haematol. 84: 586-594.
30. Schneider, P., R. Schwenzer, E. Haas, F. Muhlenbeck, G. Schubert, P. Scheurich, J. Tschopp, and H. Wajant. 1999. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur. J. Immunol. 29: 1785-1792.
31. Sumida, T., T. T. Hoa, H. Asahara, T. Hasunuma, and K. Nishioka. 1997. T cell receptor of Fas-sensitive T cells in rhumatoid synovium. J. Immunol. 158: 1965-1970.
32. Palao, G., B. Santiago, M. Galindo, M. Paya, J. C. Ramirez, and J. L. Pablos. 2004. Down-regulation of FLIP sensitizes rheumatoid synovial fibroblast to Fas-mediated apoptosis. Arthritis Rheum. 50: 2803-2810.
33. Ichikawa, K., W. Liu, M. Fleck, H. Zhang, L. Zhao, T. Ohtsuka, Z. Wang, D. Liu, J. D. Mountz, M. Ohtsuki, et al. 2003. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J. Immunol. 171: 1061-1069.
34. Mould, A. W., I. D. Tonks, M. M. Cahill, A. R. Pettit, R. Thomas, N. K. Hayward, and G. F. Kay. 2003. vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced model of arthritis. Arthritis Rheum. 48: 2660-2669.
35. Peacock, D. J., M. L. Banquerigo, and E. Bran. 1992. Angiogenesis inhibition suppresses collagen arthritis. J. Exp. Med. 175: 1135-1138.
36. Thorbecke, G. J., R. Shah, C. H. Leu, A. P. Kuruvilla, A. M. Hardison, and M. A. Palladino. 1992. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89: 7375-7379.
37. Williams, R. O., M. Feldman, and R. N. Maini. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89: 9784-9788.
38. Piguet, P. F., G. E. Grau, C. Vesin, H. Loetscher, R. Gentz, and W. Lesslauer. 1992. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77: 510-514.
39. Wooley, P. H., J. Dutcher, M. B. Widmer, and S. Gillis. 1993. Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 151: 6602-6607.
40. Saidenberg-Kermanac'h, N., A. Corrado, D. Lemeiter, M. C. deVernejoul, M. C. Boissier, and M. E. Cohen-Solal. 2004. TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35: 1200-1207.
41. Mageed, R. A., G. Adams, D. Woodrow, O. L. Podhajcer, and Y. Chernajovsky. 1998. Prevention of collagen-induced arthritis by gene delivery of soluble p75 tumour necrosis factor receptor. Gene Ther. 5: 1584-1592.
42. Liu, Z., X. Xu, H. Hsu, A. Tousson, P. Yang, Q. Wu, C. Liu, S. Yu, H. Zhang, and J. D. Mountz. 2003. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J. Clin. Invest. 112: 1332-1341.
43. Tu-Rapp, H., A. Hammermuller, E. Mix, H. Kreutzer, R. Goerlich, H. Kohler, H. Nizze, H. Thiesen, and S. M. Ibrahim. 2004. A proinflammatory role for Fas in joints of mice with collagen-induced arthritis. Arthritis Res. Ther. 6: R404-R414.
44. Tellander, A. C., E. Michaelsson, C. Brunmark, and M. Andersson. 2000. Potent adjuvant effect by anti-CD40 in collagen-induced arthritis. Enhanced disease is accompanied by increased production of collagen type-II reactive IgG2a and IFN-γ. J. Autoimmun. 14: 295-302.
45. Yoshioka, T., A. Nakajima, H. Akiba, T. Ishikawa, G. Asano, S. Yoshino, H. Yagita, and K. Okumura. 2000. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol. 30: 2815-2823.
46. Racke, M. K., A. Bonomo, D. E. Scott, B. Cannella, A. Levine, C. S. Raine, E. M. Shevach, and M. Rocken. 1994. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180: 1961-1966.
47. 1 mice. J. Immunol. 158: 1466-1472.
48. Nicholson, L. B., and V. K. Kuchroo. 1996. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr. Opin. Immunol. 8: 837-842.